Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results GlobeNewswire - Thu Aug 13, 7:30AM CDT

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor A newly-formed...

OVID : 2.93 (+3.17%)
Ovid Reports Tomorrow With Its Cash Runway Already Priced In Barchart - Tue Aug 11, 4:05PM CDT

Barchart Research What to Expect from OVID Earnings OVID Generated August 11, 2026 Current Price $2.58 EPS Estimate $$-0.10 Consensus Rating Strong Buy Average Move 11.82% Ovid Reports Tomorrow With Its...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development GlobeNewswire - Wed Jul 8, 6:00AM CDT

Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business Officer Charles Carter promoted to Chief Financial Officer, reflecting...

OVID : 2.93 (+3.17%)
Ovid Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Jun 4, 6:00AM CDT

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors GlobeNewswire - Wed Jun 3, 6:00AM CDT

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results GlobeNewswire - Tue May 12, 6:00AM CDT

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety,...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Reports Tomorrow With One Clinical Milestone Cleared and Another Still Unproven Barchart - Mon May 11, 4:06PM CDT

Barchart Research What to Expect from OVID Earnings OVID Generated May 11, 2026 Current Price $2.80 EPS Estimate $$-0.12 Consensus Rating Strong Buy Average Move 12.33% Ovid Therapeutics Reports Tomorrow...

OVID : 2.93 (+3.17%)
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 GlobeNewswire - Wed Apr 8, 7:00AM CDT

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Wed Mar 18, 5:05AM CDT

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal...

OVID : 2.93 (+3.17%)
Ovid Therapeutics Announces Pricing of $60 Million Private Placement GlobeNewswire - Wed Mar 18, 5:00AM CDT

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from...

OVID : 2.93 (+3.17%)

Barchart Exclusives

This High-Yield Exchange Stock Just Raised Its Dividend by Nearly 20% Barchart - Wed Aug 19, 6:30PM CDT
Cboe Global Markets raised its quarterly dividend by 19% to $0.86 per share on Aug. 13, marking the 16th consecutive year of increases, supported by strong options trading volumes and solid second-quarter results. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.